OMER Omeros Corp: Accounting Value of Company

Official company branding of Omeros Corp. (OMER)

Omeros Corporation brings together elite immunologists and biochemists united by the goal of treating rare diseases. The business relies on the development of MASP-2 inhibitors for the treatment of renal and hematological pathologies, covering the immunology segment. This price chart on GURU.Markets, where the indicator is -0.05, illustrates the company's dependence on external investments and patents due to the lack of profitable products currently in the development stage.

OMER: Omeros Corp. Book Capitalization 07/04/2022 - 10/30/2026

OMER (Omeros Corp.): analytical breakdowns and indicator data

- price and consensus price forecast:
Market Price Omeros Corporation|OMER - Price Target Chart
- company stock capitalization data:
Market Value Omeros Corp|OMER - Total Company Value
- issuer book value statistics:
Equity per Share Omeros|OMER - Book Capitalization|Market-to-Book Ratio omeros.com|OMER - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital Omeros Corporation|OMER - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Omeros Corporation|OMER - Company Debts|Debts to Book Value Omeros Corp|OMER - Company Long-Term Debt|Short-Term Debt Omeros|Quick Liquidity Indicator omeros.com
- earnings and valuation multiples information:
OMER - Net Profit
Initial company analysis:OMER, Omeros
Mass-produced product of omeros.com

Book value represents the value of a company's net assets minus all liabilities. This metric is calculated by aggregating public equity data, reflecting the fundamental "anchor" of value. Monitoring book value allows for an assessment of the business's internal resilience to market volatility. However, for Omeros Corporation (OMER), this indicator is critical. FDA delays regarding narsoplimab create a real threat of funding shortages for debt servicing.

Competitor analysis

Total Stockholders' Equity Biogen Idec|Neurocrine Biosciences (NBIX) - Company Book Value|regencellbioscience.com - Accounting Value of Company|Company Book Value Axsome Therapeutics, Inc.|Accounting Capitalization ACAD (ACADIA Pharma)|Book Capitalization XENE|VKTX - Total Stockholders' Equity|Supernus Pharmaceuticals - Company Net Assets|Book Capitalization catalystpharma.com CPRX|DNLI - Company Book Value|Accounting Value of Company HRMY (Harmony Biosciences Inc)|Biohaven Pharmaceutical (BHVN) - Company Book Value|Total Stockholders' Equity Amylyx Corp (AMLX)|Company Book Value Trevi Therapeutics|Total Stockholders' Equity praxismedicines.com PRAX|Company Book Value Anavex Life Sciences Corp. (AVXL)|Company Net Assets CeriBell Inc CBLL|Book Capitalization PRTA (prothena.com)|Alector Inc. (ALEC) - Total Stockholders' Equity|ANNX - Company Book Value|Accounting Value of Company NGNE (neurogene.com)|AC Immune SA (ACIU) - Company Book Value|Total Stockholders' Equity Voyager Therapeutics Inc (VYGR)|Company Book Value Neumora Therapeutics Inc|Scilex Holding Company, Inc. (SCLX) - Book Valuation of Business|Company Net Assets TVGN (Tevogen Bio Holdings)|ACOG (alphacognition.com) - Accounting Value of Company|Book Capitalization CGTX (Cognition Therapeutics)|IKT - Company Net Assets|SAVA - Company Book Value|Total Stockholders' Equity Assertio Holdings, Inc.|coyatherapeutics.com (COYA) - Company Book Value|Vistagen - Accounting Value of Company|Company Book Value Ovid Therapeutics Inc|Acumen Pharmaceuticals Inc. - Net Asset Value|Company Book Value CervoMed Inc (CRVO)|ATHE - Total Stockholders' Equity|Company Book Value Clene CLNN|Accounting Value of Company PEPG|Jupiter Neurosciences Inc - Book Capitalization|RLMD - Book Capitalization|ANVS (Annovis Bio Corp) - Company Net Assets|GRCE: Total Net Assets|AIFF (Firefly Neuroscience, Inc) - Book Capitalization|ANEW Medical, Inc. (KLTO) - Book Valuation of Business|Company Book Value NeuroSense Therapeutics (NRSN)|RVPH - Total Stockholders' Equity|Company Book Value MetaVia MTVA|NRXS: Accounting Capitalization|HSDT - Company Book Value|Total Stockholders' Equity Passage Bio, Inc.|bionomics.com.au (NEUP) - Company Book Value|Company Net Assets Minerva Neurosciences Inc|ATHA (Athira) - Book Capitalization|Total Stockholders' Equity Addex ADXN|Company Book Value Alzamend Neuro, Inc. (ALZN)|CYCN (cyclerion.com) - Accounting Value of Company|Company Book Value Protagenic Therapeutics, Inc. PTIX|KTTA: Accounting Capitalization|Cortigent Medical - Book Capitalization|Total Stockholders' Equity Avenue Therapeutics Inc|BCLI (Brainstorm Cell) - Company Net Assets|caratherapeutics.com (CARA) - Book Capitalization|Company Book Value Chromocell Therapeutics Corp.|ELYM: Accounting Value of Company|Company Book Value Intra-Cellular Therapies (ITCI)|LBPH - Total Stockholders' Equity|Company Book Value Marinus Pharmaceuticals MRNS|nkgenbiotech.com (NKGN) - Total Stockholders' Equity|NRBO - Company Book Value|Sage Therapeutics Inc. (SAGE) - Company Net Assets|SNPX: Book Capitalization|Total Stockholders' Equity Trevena Inc (TRVN)|Company Book Value Vigil Neuroscience Inc.|WENA: Accounting Value of Company|Company Book Value Cerevel Therapeutics, Inc. (CERE)